Rethinking prostate cancer screening in transgender women
Canadian Urological Association Journal · 14.01.2025 · 19 (5)
DOI: 10.5489/cuaj.8994 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Canadian Urological Association Journal, online erschienen am 14.01.2025. Verfasst von Asmaa Ismail und 6 weiteren Autor:innen. Beteiligte Einrichtung: Grande Prairie Regional Hospital, Grande Prairie, AB, Canada. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Introduction
Over the years, the number of people openly identifying as transgender has steadily increased, leading to a greater need for transgender-specific healthcare information. Among transgender women (TW), there remains a risk of prostate cancer since the prostate is not removed during gender-affirming hormone therapy (GAHT) or surgery; however, there is limited knowledge about prostate cancer screening in the transgender population. Although there are few reported cases of prostate cancer screening or prostate-specific antigen (PSA) testing in TW, the impact of hormone therapies on PSA levels is well-documented. Notably, GAHT for TW and hormone therapy for treating prostate cancer share similarities. Drawing on these similarities, we aimed to develop guidelines for baseline PSA levels and prostate cancer screening in TW.
Methods
Through a systematic review, we examined the existing PubMed publications on PSA levels and prostate cancer screening in TW, as well as expected PSA levels in patients with prostate cancer undergoing hormone therapies. We also investigated other aspects considered for the diagnosis of prostate cancer. Given the limited research on TW, we also included relevant case studies. These publications and case reports were reviewed and analyzed to create a comprehensive overview of expected baseline PSA levels and prostate cancer screening guidelines for TW.
Results
Currently, there are no established guidelines for PSA or prostate cancer screening in TW; however, these case studies indicated a range of PSA values from 3.3 to
Autor:innen und Institutionen
- Grande Prairie Regional Hospital, Grande Prairie, AB, Canada.
- Thunder Bay Regional Health Science Centre, Thunder, Bay, ON, Canada.
Zitieren
APA
Ismail, A., Hadi, R. A., Alaradi, H., Jani, K., Elmansy, H., Zakaria, A., & Kotb, A. (2025). Rethinking prostate cancer screening in transgender women. Canadian Urological Association Journal, 19(5). https://doi.org/10.5489/cuaj.8994
Vancouver
Ismail A, Hadi RA, Alaradi H, Jani K, Elmansy H, Zakaria A, et al. Rethinking prostate cancer screening in transgender women. Canadian Urological Association Journal. 2025;19(5). doi:10.5489/cuaj.8994
BibTeX
@article{Ismail2025,
author = {Ismail, Asmaa and Hadi, Ruba Abdul and Alaradi, Husain and Jani, Krishna and Elmansy, Hazem and Zakaria, Ahmed and Kotb, Ahmed},
title = {Rethinking prostate cancer screening in transgender women},
journal = {Canadian Urological Association Journal},
year = {2025},
volume = {19},
number = {5},
doi = {10.5489/cuaj.8994}
}
EUVIMED